Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

28 Jan 2009 07:00

Embargoed Release: 07:00hrs Wednesday 28 January 2008

SOPHEON PLC ("Sopheon" or the "Group") TRADING UPDATE

Sopheon plc, the international provider of software and services that improve the financial return from innovation and product development investments, announces significant progress in year-on-year operating performance. Total revenues for the year ended 31 December 2008 are expected to exceed £9 million compared to £6.3 million in 2007. The year-end close process is not complete, but initial indications are that the Group's EBITDA result will be in line with analyst expectations of £900,000. The EBITDA result in 2007 was £113,000.

License fees comprised a higher percentage of the revenue mix in 2008 than in the prior year. Approximately 65% of revenues in 2008 were derived from existing customers, demonstrating their commitment to Sopheon solutions and underpinning the revenue potential for the coming year. We entered 2009 with a base of recurring revenue - comprising annual maintenance, hosting and rental license contracts - that exceeded £3.6 million. Adding ongoing services projects contracted in 2008 to this recurring base, takes full-year revenue visibility* for 2009 to over £4 million. Looking ahead, the sales pipeline remains resilient, in spite of the economic turmoil. The Group has designed its software to help companies that need to exercise cost control in the short-term, while driving forward innovation to meet their long-term strategic goals. In the current climate, this is a strong selling point for Sopheon's solution. Nevertheless, the Group has adopted a prudent stance in its cost management, and will continue to do so in these uncertain times.

As at 31 December 2008, the Group had gross cash balances of over £2.5 million.

Financial expectations noted above are subject to the completion of the year-end financial close and audit processes. Sopheon plans to issue its preliminary results for the year ended 31 December 2008 on 26 March 2009.

* A definition of how visibility is calculated was provided in our announcement of 25 June 2008.

Barry Mence, Chairman, commented:

"We are very pleased to show such material progress in 2008. Market turbulence makes it hard to predict business development in 2009. We are however very encouraged by the apparent match between our software and the needs of major corporations looking to achieve cost containment while continuing to invest in innovation to ensure their future. Our solutions are ideally placed to support such companies in their efforts to achieve this objective. "

For further information contact:

Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 207 245 1100 Arif Karimjee, CFO Vikki Krause Hansard Communications Tel : + 44 (0) 207 7515 922906 Paul Davies Seymour Pierce Corporate Tel: +44 (0) 20 7107 8000 Finance Claire Verhagen Citigate First Financial Tel : + 31 (0) 205 754 010About Sopheon

Sopheon is an international provider of software and services that help organisations improve the business impact of product innovation. Sopheon's Accolade® solution automates the product innovation process and provides decision support for the management of product portfolios. Its Vision Strategistâ„¢ offering automates the strategic product roadmapping process, allowing users to visualise and forecast the future of products, markets and technologies. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Euronext in the Netherlands. For more information, please visit www.sopheon.com.

vendor
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.